Lupin Limited — Updates, 17-04-2025: Press Release

Lupin has received the Establishment Inspection Report (EIR) from the US FDA for its drug-medical device combination products at the injectable facility in Nagpur, India. This report follows an inspection that took place from June 10 to June 13, 2024. Nilesh Gupta, Managing Director, expressed satisfaction with the EIR, emphasizing Lupin's commitment to addressing unmet healthcare needs through the production of complex generics and essential products. This development could enhance the company's market standing and operational capacity in the pharmaceutical sector, presenting a positive outlook for Lupin's future initiatives and product offerings. Investors should monitor the potential growth stemming from this regulatory approval.